Search

everythinglearnresearchcommunity

for

Search:↓

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Low-penetration genes might help personalize colorectal cancer prevention.

4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

A new method improves betulin delivery and shows promise in cancer treatment.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Itraconazole helps improve tough skin infections but may not prevent them from coming back.

Mitochondrial features can predict colorectal cancer outcomes and improve immunotherapy.

Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Mannitol diuresis allows higher doses of cis-platinum for testicular cancer treatment without increasing kidney damage.

C.I. Acid Orange 3 caused cancer in female rats but not in male rats or mice.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Compound 7p shows strong potential as an anticancer agent.

Gefitinib can cause rare scarring hair loss.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Topoisomerase inhibitors can cause hair loss, skin rash, hand-foot syndrome, and nail changes.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Erlotinib can cause hair loss and texture changes.